The Association of Multisite Research Corporations (AMRC) today announced the addition of three new members,Rovia Clinical Research, K2 Medical Research, and Eximia, further expanding its representation of leading multisite research organizations across the United States and internationally.
Since launching in January 2025, AMRC has united 15 multisite corporations under one umbrella and has already delivered meaningful impact for the industry. Achievements include:
- Hosting a series of informative webinars spotlighting regulatory change, site efficiency, and sponsor engagement.
- Publishing editorial content to clearly define the MCRC model and its unique advantages for trial sponsors, CROs, investigators, and patients.
- Creating opportunities for dialogue between regulators, sponsors, CROs, and MCRCs to strengthen the industry’s collaborative approach.
- Preparing to launch an industry-wide consultation later this year to define priorities for 2026 and beyond.
With the addition of these three new members, AMRC’s collective footprint now represents more than 530 sites, over 1,600 principal investigators and nearly 9,000 employees dedicated to advancing the quality, efficiency, and scalability of clinical trials.
Jim Kremidas, AMRC Executive Director, commented: “Welcoming Rovia, K2, and Eximia to AMRC underscores the rapid momentum we’ve seen since our launch earlier this year. In just nine months, we’ve built a community of 15 leading multisite research corporations, published a positioning paper that defines the value of the MCRC model, convened regulators, sponsors, and CROs in direct dialogue with our members, and created a platform for knowledge-sharing through webinars and editorial content.
“The addition of these three respected organizations not only strengthens our collective voice but also reinforces our commitment to raising the bar on quality, efficiency, and access in clinical research. Looking ahead, our upcoming industry-wide consultation will ensure we capture the perspectives of the entire ecosystem as we shape the priorities for 2026 and beyond.”
New Members
Rovia Clinical Research
Rovia Clinical Research is a multi-specialty site network with over 18 years of experience. Operating across 12 sites with 80+ investigators, Rovia specializes in endocrinology, obesity, cardiology, gastroenterology, neurology, ophthalmology, and infectious disease. With a proven history of more than 750 trials completed, Rovia is recognized for rapid study start-up, enrolment target achievement, best-in-class patient retention, and high-quality data delivery. https://roviaclinical.com/
Patricio Casillas, CEO of Rovia Clinical Research, said: “We joined AMRC because of the passion we have to level up the quality of site performance in the U.S. We firmly believe that aggregating sites into networks helps elevate and standardize the quality of research and outcomes for patients, investigators, and life science customers. Our model expands access to experimental breakthrough products, especially in underserved areas. We share AMRC’s vision of transforming clinical research by delivering fast, cost-effective results with superior data quality.”
K2 Medical Research
K2 Medical Research is a privately owned clinical research organization with headquarters in Orlando, Florida, and facilities across Florida, Tennessee, and Rhode Island. Specializing in multiphasic clinical trials, K2 has brought 80 new treatments and devices to market by leveraging its combined 700 years of research experience across its network. K2’s mission is to improve health outcomes locally and globally while maintaining the highest standards of patient safety and privacy. https://k2med.com/
Sean Stanton, Co-Founder of K2 Medical Research, said: “K2 joined AMRC because we believe in the collective strength of uniting leading research organizations. Together, we can accelerate progress, share best practices, and expand patient access to high-quality clinical trials while raising the standard for efficiency and innovation across the industry.
“The AMRC model is transforming how research is delivered. By leveraging the scale and resources of multisite organizations, we can streamline operations, reduce redundancies, and bring therapies to patients faster, all while ensuring consistency and quality across every study.”
Eximia Research
Eximia Research is a global healthcare and research network focused on advancing collaborative medical innovation through partnerships with industry and academia. With operations spanning multiple therapeutic areas, Eximia is dedicated to improving trial quality and access through a model built on integration, collaboration, and patient-centricity. https://eximiaresearch.com/
Dr. Ella Grach, CEO of Eximia, said: “Joining AMRC reflects our commitment to advancing collaborative research and innovation. We see tremendous potential in aligning with likeminded organizations to accelerate progress, share knowledge, and drive meaningful change in medical research. This partnership will strengthen our voice and broaden our reach.”
Ends
Notes to editors
AMRC existing members :
- Alcanza Clinical Research
- Alliance for Multispecialty Research (AMR)
- CenExel
- Centricity Research
- DM Clinical Research
- Evolution Research Group (ERG)
- Flourish
- Javara
- Helios Clinical Research
- Headlands Research
- IMA Clinical Research
- Paradigm Clinical Research
- Pratia
- Tekton Research
- Velocity Clinical Research
About AMRC
The Association of Multisite Research Corporations (AMRC) is a nonprofit organization dedicated to advancing the use of multisite clinical research corporations in the global clinical trial ecosystem. Through advocacy, collaboration, and education, AMRC aims to transform clinical trials to improve patient outcomes, data quality, and operational efficiency. Visit amrc.org for more information.
